PharmiWeb14h
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)[1] and OXB,[2] today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
Viral Vector And Plasmid DNA Manufacturing Market size to Show Positive Growth at a CAGR of 20.4% by 2034
The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...
News Medical3d
Human organoids for AAV capsid selection
Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...
News Medical3d
Gene therapy breakthrough offers hope for severe Dravet syndrome cases
AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
DeFiance on MSN3d
AAV Innovation Summit 2025 to Explore AI and Vector Design in Gene Therapy
The AAV Innovation Summit 2025, hosted by Form Bio, will bring together top experts in gene therapy to discuss the latest ...
Gene Therapy: Revolutionizing Medicine By Tackling Diseases At Their Genetic Roots
Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...
CNET16d
QLED vs. OLED: What's the Difference and Which Is Better?
David reviews TVs and leads the Personal Tech team at CNET, covering mobile, software, computing, streaming and home entertainment. We provide helpful, expert reviews, advice and videos on what ...
Taiwan News16d
Appointment of Joint Corporate Broker and Joint Financial Adviser
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force ... development and manufacturing expertise in lentivirus, ...
Morningstar16d
Appointment of Joint Corporate Broker and Joint Financial Adviser
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors ... expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other ...